S
Stephen R. Kaplan
Researcher at Brown University
Publications - 22
Citations - 20013
Stephen R. Kaplan is an academic researcher from Brown University. The author has contributed to research in topics: Arthritis & Complement system. The author has an hindex of 16, co-authored 22 publications receiving 19416 citations. Previous affiliations of Stephen R. Kaplan include Yale University & Rhode Island Hospital.
Papers
More filters
Journal ArticleDOI
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
TL;DR: The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA).
Journal ArticleDOI
The Clinical Spectrum of Gouty Arthritis in Women
TL;DR: Gout in women is overwhelmingly postmenopausal, apparently associated with diuretic therapy and renal insufficiency independent of the effects of age, and apparently associated in men with crystal-proved gout as well.
Journal ArticleDOI
Progressive systemic sclerosis: Mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients
TL;DR: Future therapeutic trials in PSS should be designed with the recognition that a subgroup of patients with this disorder will have a rapidly progressive disease course, and close observation of PSS patients during the first 12 to 18 months may serve to identify those individuals who will undergo an accelerated disease course.
Journal ArticleDOI
Treatment of Advanced Wegener's Granulomatosis with Azathioprine and Duazomycin a
TL;DR: Azathioprine (Imuran) was used in combination with duazomycin A, a glutamine antagonist, for treatment of two patients with advanced Wegener's granulomatosis with renal involvement.
Journal ArticleDOI
Gold lung: Recent developments in pathogenesis, diagnosis, and therapy
TL;DR: When patients receiving gold therapy present with signs and symptoms consistent with an acute or subacute hypersensitivity pneumonitis, the gold therapy should be withheld and a diagnostic workup initiated.